All News

From proposed transparency rules to Medicare price negotiation programs, the stakes are high for pharmacy reimbursement and the sustainability of independent practices.

The FDA clears secukinumab for patients 12 years and older with tough hidradenitis suppurativa, offering weight-based IL‑17A biologic relief and new guidance on screening and safety.

Annie Lambert, PharmD, BCSCP, discusses the key approaches to ensuring safe and effective dispensing of compounded GLP-1 medications.

From patient perspectives on acceptability, researchers assess the impact of pharmacist-led point-of-care testing services in rural Tennessee communities.

Remote hub model in New Zealand upskills pharmacists to launch automated insulin delivery faster, expanding equitable access for type 1 diabetes.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.

Amid increased use of artificial intelligence across pharmacy, researchers assess pharmacists’ propensity to trust the emerging automated technology.

US pharmacists can prescribe contraception through streamlined pharmacy care, expanding access; supporting maternity deserts; and improving women’s health.

FDA approves Wellcovorin for rare FOLR1 cerebral folate deficiency, spotlighting real-world evidence, dosing goals, and key drug-interaction risks.

Highlighting 'prone to abuse' and adverse effects as the driver of this bill, Senator Hawley aims to reverse an FDA decision made over 25 years ago.

A study finds prior-authorization bans do not boost buprenorphine retention for patients on private insurance.

Mark Cuban Cost Plus Drug Company challenges pharmacy benefit managers' opacity, expands affordable drug access, and supports community pharmacies.

Drug shortages remain one of the most persistent challenges in pharmacy practice, but emerging technologies like AI are beginning to shift the landscape for pharmacies and public health as a whole.

In regard to potentially dangerous exposure to parabens, researchers aim to clarify the role of OTC liquid drugs among children.

This episode explores a specific generalization within pharmacy practice that leaders should actively avoid while simultaneously looking toward overcoming key hurdles affecting team members.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.

Through the lens of geographic and racial accessibility, researchers explore OTC naloxone sales and costs in North Carolina.

Pharmacists’ word choices shape insulin-pump trust, reduce diabetes stigma, and uncover hidden needs—boosting adherence and A1C outcomes.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Harps pharmacists reveal how smart workflow powers point‑of‑care testing, prescribing, and billing—scalable clinical services for regional chains.

Lani Bertrand, senior director of clinical marketing & thought leadership at Omnicell, discusses the consistent drivers of drug shortages in the US.

The FDA approves Sotyktu, the first selective TYK2 oral pill for active psoriatic arthritis, improving joints and skin with key safety monitoring.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

GLP-1 diabetes drugs show promise in cutting addiction risk and overdose deaths, hinting at new options for substance use disorder prevention and care.

Once weekly petrelintide, a long-acting amylin analog, delivers up to 10.7% weight loss with placebo-like gastrointestinal tolerability in phase 2.